文献速递细胞病理与分子病理

SMARCB1缺陷性肿瘤的细胞病理与组织病理特征及其与分子和免疫组化结果的相关性

Cytopathologic and histopathologic characteristics of SMARCB1 deficient neoplasm and correlation with molecular and immunohistochemical findings.
PubMed 文献 · Hum Pathol · 2025-11-10

该研究回顾10年病理档案中SMARCB1(INI-1)表达缺失的肿瘤54例,涵盖浆液、细针穿刺、活检和手术切除标本。研究发现特征性细胞形态包括低分化癌样多形性细胞、基底样、横纹肌样或上皮样肉瘤,且角蛋白常阳性,并伴有复杂遗传学异常。结论建议对形态怪异、低分化或多形性显著的肿瘤进行SMARCB1(INI-1)辅助检测。

要点

  • SMARCB1缺陷性肿瘤形态高度异质,细胞学可表现为低分化癌样、基底样、横纹肌样或上皮样。
  • 肿瘤常表达角蛋白,易误诊为癌,需结合SMARCB1(INI-1)免疫组化确诊。
  • 对形态怪异、低分化或多形性显著的肿瘤应考虑SMARCB1(INI-1)辅助检测。

核心结论

  • SMARCB1缺陷性肿瘤具有高度变异的细胞和组织形态,细胞学识别对临床管理至关重要。
  • 对形态怪异、低分化或多形性显著的肿瘤应考虑SMARCB1(INI-1)辅助检测。

研究设计与样本

  • 回顾性研究,检索10年病理档案中诊断SMARCB1缺陷性肿瘤且SMARCB1(INI-1)表达异常的病例。
  • 共纳入54例SMARCB1(INI-1)免疫组化完全缺失的病例,包括5例浆液、10例细针穿刺、18例活检芯和21例手术切除。
  • 另纳入10例SMARCB1(INI-1)部分缺失的病例。
  • 中位年龄35.8岁(范围14天至87岁),女性与男性比为1.07:1.00。
  • 最常累及部位依次为头颈(n=14)、中枢神经系统(n=11)、淋巴结(n=8)、胸部/肺(n=6)、肝(n=5)及其他(n=10)。

主要发现

  • 除已报道的形态模式外,特征性细胞形态包括低分化癌样多形性肿瘤细胞、基底样、横纹肌样或上皮样肉瘤。
  • 这些肿瘤常呈角蛋白染色阳性。
  • 鉴定出复杂遗传学异常,包括SMARCB1/INI-1、PIK3C2B、RAF、MAP3K14、FBXO11等异常。

临床怎么用

  • 对形态怪异、低分化或显著多形性的肿瘤,应考虑进行SMARCB1(INI-1)免疫组化检测。
  • 细胞学识别SMARCB1缺陷性肿瘤对适当临床管理至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SMARCB1 deficient neoplasm is an aggressive and heterogeneous group of neoplasms. The morphology of the neoplasm is highly variable. Recent clinical trials show that targeted therapy with EZH2 inhibitor tazemetostat can improve patients' survival. Thus, it is important to recognize the entity for appropriate clinical management. MATERIAL AND METHODS: The pathology archive was searched over 10-year period for cases with diagnosis of SMARCB1 deficient neoplasm and aberrant expression of SMARCB1 (INI-1). Cyto- and histomorphology, immunohistochemistry (IHC) and molecular findings were characterized. RESULTS: 54 cases with complete loss of SMARCB1 (INI-1) on IHC staining were identified, including 5 serous fluids, 10 fine needle aspirations (FNA), 18 biopsy cores and 21 surgical resections. The median age of patients was 35.8 years, ranging from 14 days to 87 years. The female to male ratio was 1.07:1.00. The most involved anatomic sites in descending order were: head and neck (n = 14), CNS (n = 11), lymph node (n = 8), thorax/lung (n = 6), liver (n = 5) and others (n = 10). In addition to published morphology patterns, characteristic cytomorphology included phenotypic features of poorly differentiated carcinoma with pleomorphic tumor cells, basaloid, rhabdoid or epithelioid sarcomas. These tumors had frequently positive cytokeratin stains. Complex genetic abnormalities were identified, including aberrant SMARCB1/INI-1, PIK3C2B, RAF, MAP3K14, FBXO11 and others. 10 cases of partial loss of SMARCB1 (/INI-1) were also included. CONCLUSIONS: The ancillary testing of SMARCB1 (INI-1) should be considered in a subset of patients whose tumor demonstrates bizarre cytomorphology, especially in poorly differentiated or markedly pleomorphic tumors. The cytological recognition is critical for appropriate management.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Sanchez SI, Adams C, Illei P, et al. Cytopathologic and histopathologic characteristics of SMARCB1 deficient neoplasm and correlation with molecular and immunohistochemical findings. Hum Pathol. 2025. PMID: 41224025. doi:10.1016/j.humpath.2025.105980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。